Microcytometer enrichment and detection of colon cancer*

结肠癌的微细胞计数富集和检测*

• 批准号: 7021339
• 负责人: JOHN Charles GERDES
• 金额: $ 10万
• 依托单位: MICRONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-03 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7021339
• 关键词: blood; clinical research; colon neoplasms; microfluidics; neoplasm /cancer; neoplastic cell

DESCRIPTION (provided by applicant): Circulating tumor cells in blood are detectable in late stage colon cancer patients. However, adequately sensitive and specific methods have not been identified for early diagnosis or detection of micrometastatic cells. Also, current approaches are cumbersome and therefore not suitable for use by clinical diagnostic laboratories. Routine clinical use will require a substantial improvement in rare tumor cell enrichment from blood, identification of an appropriate tumor marker that identifies the majority of early stage patients without false positives or negatives, and an integrated methodology more compatible with clinical laboratory testing. Our ultimate goal is to enable reproducible detection and confirmation of rare colon cancer cells from blood in an economical integrated clinical laboratory test or point-of-care platform. During phase I we will confirm the feasibility of our approach using whole blood spiked with colon cancer cells. We propose a credit-card sized microfluidic cell sorting device for sorting and detecting tumor cells in blood that will be much faster and have high specificity and several orders of magnitude greater sensitivity than current flow cytometry. Individual steps will be performed using on-card fluidic movement and valving logic, with final performance enabled through the design of an integrated microfluidic circuit that automates the process. The completion of our phase I specific aims will result in a bread board platform that will be tested using clinical specimens from colon cancer patients in collaboration with Fred Hutchinson Cancer Research Center. Colorectal cancer affects approximately 147,000 people in the United States each year and is most effectively treated when diagnosed at an early stage. Consequently, colon cancer screening is an effective means for decreasing mortality secondary to colon cancer. Current colon cancer screening methods include either sigmoidoscopy or colonoscopy. However, only 25-35 percent of adults undergo screening because of fear of discomfort from the bowel preparation and, in the case of colonoscopy, the cost of the screening test. The colon cancer screening test we will develop uses a blood specimen for diagnosis to overcome the drawbacks of current screening methods. The approach leverages recent advances in molecular assays together with Micronics' microfluidics and cell sorting technologies to develop an assay that can be utilized in routine clinical or point of care settings. This will result in better screening compliance and save lives through earlier detection.

描述（由申请人提供）： 在晚期结肠癌患者中可以检测到血液中的循环肿瘤细胞。然而，尚未确定足够灵敏和特异的方法用于早期诊断或检测微转移细胞。此外，当前的方法很麻烦，因此不适合临床诊断实验室使用。常规临床使用需要显着改善从血液中富集罕见肿瘤细胞的能力，鉴定出能够识别大多数早期患者而不会出现假阳性或阴性的适当肿瘤标志物，以及与临床实验室检测更兼容的综合方法。我们的最终目标是在经济的综合临床实验室测试或即时护理平台中实现对血液中罕见结肠癌细胞的可重复检测和确认。在第一阶段，我们将确认我们使用掺有结肠癌细胞的全血的方法的可行性。我们提出了一种信用卡大小的微流体细胞分选装置，用于分选和检测血液中的肿瘤细胞，与当前的流式细胞术相比，该装置速度更快，特异性高，灵敏度高几个数量级。各个步骤将使用卡上流体运动和阀门逻辑来执行，并通过设计自动化该过程的集成微流体电路来实现最终性能。我们第一阶段具体目标的完成将产生一个面包板平台，该平台将与 Fred Hutchinson 癌症研究中心合作，使用结肠癌患者的临床样本进行测试。在美国，结直肠癌每年影响约 147,000 人，早期诊断时治疗效果最佳。因此，结肠癌筛查是降低继发结肠癌死亡率的有效手段。目前的结肠癌筛查方法包括乙状结肠镜检查或结肠镜检查。然而，只有 25-35% 的成年人接受筛查，因为担心肠道准备带来的不适，以及结肠镜检查的筛查费用。我们将开发的结肠癌筛查测试使用血液样本进行诊断，以克服当前筛查方法的缺点。该方法利用分子测定的最新进展以及 Micronics 的微流体和细胞分选技术来开发可用于常规临床或护理点环境的测定。这将提高筛查合规性，并通过早期检测挽救生命。